Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs

Torino, Francesco; Barnabei, Agnese; Paragliola, Rosa Maria; Baldelli, Roberto; Appetecchia, Marialuisa; Corsello, Salvatore Maria

doi:10.1089/thy.2013.0241

Cited by 99 publications

(81 citation statements)

References 236 publications

(228 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although Hashimoto disease was described as a risk factor for papillary thyroid cancer, in the current study Hashimoto disease and thyroid cancer did not occur more frequently in the same patients [21,22].…”

Section: Discussioncontrasting

confidence: 68%

Co-existence of chronic non-communicable diseases and common neoplasms among 2,462 endocrine adult inpatients – a retrospective analysis

Szychta

Lewiński

et al. 2015

Ann Agric Environ Med.

View full text Add to dashboard Cite

Szychta P, Szychta W, Lewiński A, Karbownik-Lewińska M. Co-existence of chronic non-communicable diseases and common neoplasms among 2,462 endocrine adult inpatients -a retrospective analysis. Ann Agric Environ Med. 2015; 22(4): 747-754. doi: 10.5604/12321966.1185788 Abstract Objective. To analyze the coexistence of chronic non-communicable diseases (NCDs) and common neoplasms among endocrine adult inpatients. Materials and method. The retrospective analysis was performed using clinical data of 2,462 adult patients (2,003 women and 459 men), hospitalized in the reference endocrine department. Diagnoses of 18 types of benign tumours and 16 types of malignant tumours, together with the most common 25 NCDs and demographic parameters, were all collected from the medical records. The most frequently found 6 types of benign tumours (of thyroid, pituitary, uterus, breast, adrenal and prostate) and 4 types of malignant tumours (of thyroid, breast, prostate and uterus) were taken for further statistical analyses. Results. Age predicted the existence of accumulated as well as individual types of benign and malignant tumours, whereas BMI predicted the occurrence of accumulated and some individual types of benign tumours. Accumulated as well as individual types of benign and malignant tumours coexisted more frequently with several NCDs, such as diabetes, hypertension, metabolic syndrome, osteoporosis, Graves' disease, coronary artery disease, state after cholecystectomy, thus being disorders usually resulting from excessive exposure to harmful environmental factors. The most distinct coexistence was found between breast cancer and metabolic syndrome, between breast cancer and Graves' disease, between cancer of the uterus and type 2 diabetes, between cancer of the uterus and metabolic syndrome, and between cancer of the uterus and dyslipidemia. Conclusion. The results obtained indicate a significant relationship between the most common NCDs and several cancers in endocrine adult patients, which suggests that the prevention of the former may reduce the frequency of the latter.

show abstract

Section: Discussioncontrasting

confidence: 68%

Co-existence of chronic non-communicable diseases and common neoplasms among 2,462 endocrine adult inpatients – a retrospective analysis

Szychta

Lewiński

et al. 2015

Ann Agric Environ Med.

View full text Add to dashboard Cite

show abstract

“…However, no biopsyproven ipilimumab-or nivolumab-induced AH has been reported [12]. In addition, the prevalence of anti-pituitary antibodies remains unknown in large cohorts of patients with immune-checkpoint inhibitorinduced hypophysitis, although endocrine irAEs such as destructive thyroiditis and fulminant type I diabetes mellitus have been reported in patients treated with immune-checkpoint blocking agents [9,17]. Ricciuti A et al recently reported that the human pituitary gland was the best substrate to detect anti-pituitary antibodies by indirect immunofluorescence [18].…”

Section: Discussionmentioning

confidence: 99%

“…In addition to these evidence-based immune-mediated anti-cancerous effects, ipilimumab frequently induces several endocrine immune-related adverse events (irAEs) such as hypophysitis and destructive thyroiditis as a consequence of enhanced T cell functions [8][9][10][11][12]. Although hypophysitis induced by nivolumab has also been reported, its incidence in Western countries appears to be lower than that observed with ipilimumab [12].…”

mentioning

confidence: 99%

Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma

et al. 2016

View full text Add to dashboard Cite

“…The function of the thyroid gland can be adversely impacted at various levels of the HPT axis by systemic therapies that are prescribed for the treatment of cancer [102] (Table 1). Although much better described in adults, these off-target consequences of cancer therapy will likely become more commonplace in children, given the expanding role of TKIs and immune checkpoint inhibitors in the pediatric oncology field [103, 104].…”

Section: Thyroid Dysfunction Due To Non-radioactive Systemic Therapiesmentioning

confidence: 99%

“…First described with the drug sunitinib [105], de novo primary thyroid disease can occur with many of the commercially available TKIs [102, 106-109] (Table 1). Several mechanisms for TKI-induced thyroid dysfunction have been proposed, including induction of destructive thyroiditis, inhibition of thyroid peroxidase activity, effects on thyroid hormone absorption and clearance, impaired iodide uptake, and thyroid capillary regression caused by vascular endothelial growth factor inhibition [102, 106, 107]. Destructive thyroiditis is likely a major mechanism, and this follows a typical pattern of hyperthyroidism followed by hypothyroidism [102, 110, 111].…”

Section: Thyroid Dysfunction Due To Non-radioactive Systemic Therapiesmentioning

confidence: 99%

Thyroid Sequelae of Pediatric Cancer Therapy

Waguespack

2018

Horm Res Paediatr

View full text Add to dashboard Cite

The hypothalamic-pituitary-thyroid axis is a common site of unintended, acquired disease either during or after the treatment of cancer. Children treated with external radiation therapy are at the highest risk for developing a thyroid-related late effect, but thyroid dysfunction and second primary thyroid neoplasms can also occur after treatment with radiopharmaceutical agents such as ¹³¹I-metaiodobenzylguanidine. Increasingly recognized is the development of early thyroid dysfunction as an off-target consequence of the more novel cancer therapeutics such as the tyrosine kinase inhibitors and immune checkpoint inhibitors. Thyroid sequelae resulting from irradiation may manifest only after years to decades of follow-up, and their resultant clinical symptoms may be indolent and non-specific. Therefore, lifelong monitoring of the childhood cancer survivor at risk for thyroid disease is paramount. In this comprehensive review, the myriad thyroid adverse effects resulting from pediatric cancer treatment are discussed and an overview of screening and treatment of these thyroid sequelae provided.

show abstract

Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs

Cited by 99 publications

References 236 publications

Co-existence of chronic non-communicable diseases and common neoplasms among 2,462 endocrine adult inpatients – a retrospective analysis

Co-existence of chronic non-communicable diseases and common neoplasms among 2,462 endocrine adult inpatients – a retrospective analysis

Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma

Thyroid Sequelae of Pediatric Cancer Therapy

Contact Info

Product

Resources

About